Berlin's Health Overhaul Spurs Lilly Pullback and BioNTech's 1,860-Job Restructuring
Published on 06/04/2026 at 18:04 | Redaktion boerse-global.de
The German government's proposed healthcare reforms are drawing fire from two heavyweight drugmakers, with Eli Lilly slashing its local investment by more than half and BioNTech accelerating a deep cost-cutting drive that will eliminate nearly a quarter of its workforce. The twin warnings underscore the fragile state of Germany's once-thriving pharma ecosystem.
Lilly said it would reduce planned spending at a German production site from $2.5 billion to roughly $1 billion, scrapping about 500 jobs in the process. The US group blamed the decision squarely on regulatory uncertainty, and BioNTech — itself a homegrown champion — has added its voice to the chorus of criticism. The Mainz-based company argues that the reforms risk long-term damage to Germany's appeal as a pharmaceutical hub.
BioNTech's own restructuring is already well underway. Four manufacturing sites — including those in Marburg and Tübingen — are slated for closure by the end of 2027, resulting in the loss of approximately 1,860 roles. The move is expected to generate annual savings of around €500 million by 2029, funds that management will plough into the oncology pipeline. The company now runs more than 25 phase 2 and phase 3 trials, 13 of which are considered pivotal.
The financial backdrop is strained. First-quarter revenue shrank to €118 million from €183 million a year earlier as Covid vaccine sales continued to fade, while the net loss ballooned to €532 million. BioNTech nevertheless sits on a cash pile of roughly €16.8 billion, which it is using to finance a share buyback of up to $1 billion — equivalent to about 4.2% of outstanding shares — that runs through May 2027.
Should investors sell immediately? Or is it worth buying BioNTech?
Investors have not been kind. The stock recently changed hands at €77.65, more than 20% below its level 12 months ago and well adrift of its 200-day moving average. A pair of down days following the presentation of Pumitamig data at the ASCO conference — the drug showed encouraging activity in lung cancer but failed to excite the market — drove the shares down 3.9% and then 3.2% in consecutive sessions. The relative strength index stands at 43.4, a neutral reading that offers no technical support for a rebound.
Analyst sentiment, however, remains far more optimistic than the share price suggests. Jefferies reiterated its buy rating with a $138 target on June 1. UBS upgraded the stock from Neutral to Buy shortly before, lifting its target to $135; research analyst David Dai highlighted what he sees as undervalued potential in the cancer pipeline. Bernstein's Jeffrey Walch struck a more cautious tone, initiating coverage at Market Perform with a $96 target. The consensus stands at "Moderate Buy" with a median price target of $129.56 — a chasm between Street conviction and market reality.
Adding to the uncertainty, founders U?ur ?ahin and Ă–zlem TĂĽreci are set to leave the company at year-end. The incoming management team inherits ambitious goals: ten cancer drug approvals by 2030. An application for BNT323, an antibody-based therapy, is expected later this year, and a series of late-stage readouts in the second half will test the pipeline's promise.
BioNTech at a turning point? This analysis reveals what investors need to know now.
For now, the combination of political headwinds, a shrinking workforce, and the huge gap between analyst expectations and investor sentiment leaves BioNTech in a precarious position. The next round of clinical data may shift the narrative, but the debate in Berlin over healthcare policy has added a layer of risk that no amount of oncology science can easily dispel.
Ad
BioNTech Stock: New Analysis - 4 June
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
